Form 4: Checkpoint Therapeutics CEO Disposes of Shares in Merger Completion

Checkpoint Therapeutics' CEO, James F. Oliviero III, has disposed of 3,759,929 shares of common stock in connection with a previously announced merger agreement, receiving $4.10 cash per share plus a contingent value right.

Summary

• James F. Oliviero III, CEO, President, Director, and 10% Owner of Checkpoint Therapeutics, Inc. (CKPT), reported the disposition of 3,759,929 shares of common stock.
• The transaction occurred on May 30, 2025, and resulted in Mr. Oliviero beneficially owning 0 shares directly following the reported transaction.
• The disposition was made in connection with an offer pursuant to the Agreement and Plan of Merger, originally dated March 9, 2025, and amended on April 14, 2025.
• Shareholders received $4.10 per share in cash, net to the holder, plus one contractual contingent value right (CVR) per share.
• Each CVR represents the right to receive a payment ranging from $0.20 to $0.70, contingent upon certain milestone payments related to the regulatory approval for cosibelimab in the European Union.
• The CVR milestone must be achieved within thirty-six (36) months after the date on which a marketing authorization application (MAA) or equivalent for cosibelimab receives a positive validation outcome by the European Medicines Agency (EMA).

Sentiment

Score: 7

Explanation: The filing reports the execution of a pre-announced merger, providing a defined cash value and potential future upside via CVRs for shareholders, indicating a structured exit for the company. This is generally a neutral to slightly positive event as it fulfills a prior agreement.

Positives

• The merger provides a clear exit strategy for Checkpoint Therapeutics shareholders, offering immediate cash value.
• The inclusion of a Contingent Value Right (CVR) provides shareholders with potential additional upside, ranging from $0.20 to $0.70 per share, tied to the future regulatory success of cosibelimab in the European Union.

Negatives

• The disposition of shares by the CEO signifies the completion of the merger, meaning Checkpoint Therapeutics as an independent entity will cease to exist, leading to the delisting of its shares.
• The value of the CVR is contingent on future regulatory approval, introducing uncertainty regarding the full potential payout.

Risks

• The Contingent Value Right (CVR) payment is entirely dependent on the regulatory approval of cosibelimab in the European Union, which is not guaranteed.
• There is a time limit of thirty-six (36) months for the CVR milestone to be achieved after a positive validation outcome by the European Medicines Agency, adding a time-bound risk to the potential payout.

Future Outlook

The future outlook for additional shareholder value is tied to the successful regulatory approval of cosibelimab in the European Union. The CVR payment, ranging from $0.20 to $0.70 per share, is contingent on this milestone being achieved within 36 months after a positive validation outcome by the European Medicines Agency for a marketing authorization application.

Management Comments

• The disposition of shares by James F. Oliviero III, CEO, President, and Director, was made in connection with an offer pursuant to the Agreement and Plan of Merger, dated as of March 9, 2025, and as amended on April 14, 2025.

Industry Context

Mergers and acquisitions are a common strategic move in the biotechnology and pharmaceutical industries, often driven by the desire to acquire promising drug candidates or consolidate market positions. The use of Contingent Value Rights (CVRs) is a prevalent mechanism in biotech M&A, particularly when the value of an acquired asset (like cosibelimab) is dependent on future clinical or regulatory milestones, allowing for a shared risk/reward structure between the acquirer and the target company's shareholders.

Comparison to Industry Standards

• The structure of the merger consideration, combining an upfront cash payment with a Contingent Value Right (CVR), is a common practice in biotech M&A, especially for companies with late-stage clinical assets awaiting regulatory approval.
• CVRs are frequently employed to bridge valuation gaps and provide upside potential tied to specific development or regulatory milestones, similar to deals involving companies like Array BioPharma (acquired by Pfizer) or Spark Therapeutics (acquired by Roche), where milestone payments were part of the deal structure.

Stakeholder Impact

• Shareholders: Receive a fixed cash payment and a contingent value right, providing immediate liquidity and potential future upside based on regulatory success.
• Employees: Future employment status and roles will be determined by the acquiring company post-merger, which is not detailed in this filing.

Next Steps

• The primary next step for the CVR payout is the pursuit of regulatory approval for cosibelimab in the European Union by the acquiring entity.
• Monitoring the progress of the marketing authorization application (MAA) for cosibelimab with the European Medicines Agency (EMA) will be crucial for CVR holders.

Key Dates

Keywords

Checkpoint Therapeutics, CKPT, Form 4, SEC filing, merger, acquisition, contingent value right, CVR, cosibelimab, European Union, regulatory approval, biotechnology, pharmaceuticals, insider transaction, James F. Oliviero III